The present invention relates to a method for preparation of a functionalized surface comprising the steps: a) coating of a carrier with a least one polymer selected from a polyanionic or polycationic polymer, b) addition of at least one compound to the coated carrier of step a), c) exposing the at least one polyanionic or polycationic polymer on the coated carrier of step b) to an organic solvent, resulting in compaction of the at least one polyanionic or polycationic polymer and thereby encapsulating the at least one compound, d) reversible cross-linking of the at least one polyanionic or polycationic polymer of step c) with at least one cross-linker; e) removal of the organic solvent. Furthermore, the invention relates to a functionalized surface, a functionalized surface for use in medicine and a method for releasing a compound ex vivo.

A swellable polymer based fibre and method of preparing the same for use as, for example, a wound dressing. The fibres may be formed from an aqueous dope solution containing a primary polymer and povidone-iodine (PVP-I). The aqueous dope solution is spun or extruded into a coagulation bath via a multi-hole spinneret head to form a multifilament fibre.

In various exemplary embodiments, the present disclosure provides organohydrogel fibers and a process for making the organohydrogel fibers. The organohydrogel fibers have a hydrophobic phase dispersed in a hydrophilic phase. The organohydrogel fibers contain at least one hydrophobic active pharmaceutical ingredient (API), and at least one hydrophilic API. The organohydrogel fibers can be formed into a non-woven or 3D printed patch and a replaceable backing can be attached to the patch to make an effective wound dressing. The wound dressing can deliver active pharmaceutical ingredients to the wound over a period of multiple days.

An anti-bacterial coating composition for use with a medical implant is disclosed. The anti-bacterial coating composition includes a bacteriophage cocktail that is encapsulated in beads that are embedded within a hydrogel. Also disclosed are kits containing the anti-bacterial coating composition as well as methods of producing and using the coating composition.

A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.

The present invention generally relates to the use of small particles, such as micro particles or nanoparticles, to produce a therapeutic scar such as “trans-mural” scarring or other desired “deep tissue” scarring. In one preferred embodiment, these particles can be delivered to a target location by an implant. More specifically, these particles can be incorporated into the structure of implants or into the coatings on implants. In another preferred embodiment, these small particles can be delivered directly with a catheter by electrophoresis or hydraulic pressure.

Methods are described herein for facilitating tissue regeneration in humans and other large organisms, and kits therefor. Application of an inhibitor of focal adhesion kinase (FAK) to injured tissue may reduce fibrosis and/or scarring during the wound healing process. Patient care for a large number of fibrotic diseases which affect organ function may be ameliorated by such treatment. Kits for application of the FAK inhibitor may include a hydrogel formulation encapsulating the FAK inhibitor.

The present invention provides radical crosslinked zwitterionic gels, methods of preparing the radical crosslinked zwitterionic gels, and methods of using the radical crosslinked zwitterionic gels for treating a wound.

Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. Some of the hyaluronic acid-based compositions can include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. Compared to conventional compositions that include lidocaine, some of the hyaluronic acid-based compositions disclosed herein can have an enhanced stability, for example, when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such compositions are also provided.

An example medical device includes a vascular device, such as a catheter, and an anti-thrombogenic coating on a surface of the vascular device, such as a surface likely to contact blood. The anti-thrombogenic coating includes one or more peptides configured to interact with fibrinogen in the blood, such as a first type of peptides configured to bind to fibrinogen a second type of peptides configured to inhibit conversion of fibrinogen to fibrin. The anti-thrombogenic coating also includes a polymer, such as a hydrocolloid polymer, a tunable polyethylene glycol (PEG), or other controlled release polymer configured to control release of the one or more peptides and maintain a concentration of the peptides at the surface of the anti-thrombogenic coating above a minimum inhibitory concentration, thereby inhibiting thrombin formation on the intravascular medical device.